Research :

R & D activities are at the core of Reborn India. Its constant quest for developing new products and technology has led breakthrough innovations in a wide spectrum of research areas. Reborn India's continuing R & D initiatives have strengthened its product basket with delivery of niche and complex products. Reborn India has extensively worked on para IV and 505 . Reborn India has developed products with lipid-based NDDS platform technology, which has resulted in three pharmaceutical formulations commercialized in India. Studies to extend these products into international markets are ongoing.

Reborn India's R & D strategies are focused on 2 major areas:

1. Pharmaceutical formulation development

Reborn India's primary focus area in formulation development includes:

> Developing Generic formulation to enable day 1 launch upon patent expiry   > Developing new drug formulations for existing products for life cycle management   > Development of NDA / NDF of small molecules   > Improving processes for existing formulation   > Development of difficult to develop formulations which helps Reborn India launch products having less competition in market   > Development of non-infringing formulation for launch of products in US prior to patent expiry   > Developing products based on new drug delivery platform

2. API development

Reborn India's primary focus area of API development R & D team is:

> Development of oncology and non-oncology range of products to remain in the competitive in international market   > Development of new API to support first time launch of new products in Indian market   > Development of non-infringing API process development to support para IV filing   > Manage cost efficiency of process in a mega-manufacturing environment approved by USFDA/European regulatory authorities   > Resolve complex chemistry and process related challenges and protect novel concept by filing patents to compete in the global markets